Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptive Decision-Making Under Pressure: Effects of Control Mode-Cognitive Resource Alignment on Performance Within the Contextual Control Model.

Human factors·2026
Same author

Mitigating inadvertent transitions from visual flight rules to instrument meteorological conditions in general aviation: decision-making strategies, cognitive challenges, and training Implications from an applied cognitive task analysis.

Ergonomics·2026
Same author

Clinical Impact of Laboratory Implementation of Verigene BC-GN Microarray-Based Assay for Detection of Gram-Negative Bacteria in Positive Blood Cultures.

Journal of clinical microbiology·2016
Same author

Drug-induced liver disease.

Critical care nursing clinics of North America·2010
Same author

Telbivudine: a novel nucleoside analog for chronic hepatitis B.

The Annals of pharmacotherapy·2006
Same author

Critical care pharmacy in donor management.

Progress in transplantation (Aliso Viejo, Calif.)·2004

Related Experiment Video

Updated: Jun 12, 2026

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Published on: April 28, 2020

Pharmacotherapy for hepatic encephalopathy.

Paula V Phongsamran1, Jiwon W Kim, Jennifer Cupo Abbott

  • 1Department of Clinical Pharmacy, University of Southern California School of Pharmacy, USC University Hospital Department of Pharmacy, Los Angeles, California, USA. phongsam@usc.edu

Drugs
|June 4, 2010
PubMed
Summary

Hepatic encephalopathy (HE) treatments are limited. Rifaximin shows promise as an effective and well-tolerated alternative to traditional therapies like lactulose and neomycin for managing HE.

More Related Videos

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Related Experiment Videos

Last Updated: Jun 12, 2026

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Published on: April 28, 2020

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Area of Science:

  • Hepatology
  • Gastroenterology
  • Neuroscience

Background:

  • Hepatic encephalopathy (HE) is a severe complication of liver dysfunction, characterized by neuropsychiatric abnormalities.
  • Ammonia and other gut-derived toxins play a key role in HE pathogenesis.
  • Current HE treatments, including lactulose and certain antimicrobials, have limitations and adverse effects.

Purpose of the Study:

  • To review the efficacy and safety of various therapeutic options for hepatic encephalopathy.
  • To evaluate rifaximin as a novel antimicrobial treatment for HE.
  • To compare rifaximin with established therapies like lactulose and neomycin.

Main Methods:

  • Review of clinical trials comparing rifaximin to lactulose, lactitol, and neomycin.
  • Analysis of adverse effect profiles and systemic absorption of different HE medications.
  • Assessment of the benefit-risk ratio of rifaximin in HE management.

Main Results:

  • Rifaximin demonstrates comparable efficacy to conventional HE therapies.
  • Rifaximin is associated with fewer adverse effects due to limited systemic absorption.
  • Established treatments like lactulose and antimicrobials (neomycin, metronidazole, vancomycin) have significant drawbacks, including adverse events and limited efficacy.

Conclusions:

  • Rifaximin presents a favorable benefit-risk profile for hepatic encephalopathy management.
  • Rifaximin offers an effective alternative with improved tolerability compared to traditional treatments.
  • Further research is needed to establish the cost-effectiveness of rifaximin in healthcare settings.